The mechanism involves glabridin downregulating the expression of P-glycoprotein (P-gp) and competitively inhibiting P-gp efflux pumps, thereby increasing the accumulation of DOX and paclitaxel in breast cancer cells. Here, PGP is linked to breast carcinoma.